• Skip to main content
  • Skip to primary sidebar

An Inconvenient Truth: This Is a Woman

Don’t Get Angry, Get Active!

Hide Search

Pharmaceutical Companies Seek Clarity On Evidence Needed For FDA

H. Sandra Chevalier-Batik · January 6, 2009 ·

Medical News Today

Pharmaceutical Companies Seek Clarity On Evidence Needed For FDA

05 Jan 2009

With the discovery of a growing number of predictive biomarkers for existing drugs, the question of when and how to add pharmacogenetic information to drug labels has taken on greater urgency. On December 16 the Oncologic Drug Advisory Committee (ODAC) of the Food and Drug Administration (FDA) met in Gaithersburg, MD with representatives from pharmaceutical companies Amgen and Imclone. The committee and the company representatives discussed what types of studies need to be done before existing drug labels can be amended with new biomarker information. Amgen and Imclone presented data on the effect of variants in the K-RAS gene on the efficacy of Vectibix and Eribitux, drugs used to treat colorectal cancers. They seek a label change that recommends drug usage based on predictive genetic subgroups.

FDA has stated clearly that the best way to show correlation is by developing drugs in parallel with biomarker diagnostics through prospective studies. However, genetic associations with response to a drug often emerge after the drug is already in use. In addition, in the case of Vectibix and Eribitux, there are serious ethical issues in prospectively recruiting patients with K-RAS mutations into a study for a drug that is likely to be ineffective. In briefing documents for the meeting, FDA had proposed the following requirements for retrospective device-drug co-development: well-controlled studies with sufficient sample size and biological sample acquisition for >90 percent of subjects, an assay validated by FDA, analysis by individuals blinded to the outcome results, and prior FDA review of and agreement to the analytic plan for testing the hypothesis.

The companies presented data from six retrospective studies, which showed that certain somatic mutations within the K-RAS gene render the cancer drugs ineffective. The studies on K-RAS had limitations. For example, they were performed after drug development; they used archived samples that were available for only a portion of the total subject population, and therefore possibly biased; and the K-RAS analysis was performed with an assay not yet validated by FDA. ODAC will review the FDA criteria for retrospective biomarker-drug interaction studies in light of the data presented at Tuesday’s meeting. ODAC’s consensus could help urge the FDA to update the labels of Vectibix and Eribitux to include K-RAS analysis as a prerequisite for usage. Written by – Stephanie Devaney

Issue brief – FDA regulation of genetic tests
Issue brief – Pharmacogenomics: Hope and Hype

The Genetics and Public Policy Center Johns Hopkins University
http://www.dnapolicy.org


Article URL: http://www.medicalnewstoday.com/articles/134368.php

Main News Category: Pharma Industry / Biotech Industry

Also Appears In:  Regulatory Affairs / Drug Approvals,


Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Save time! Get the latest medical news headlines for your specialist area, in a weekly newsletter e-mail. See http://www.medicalnewstoday.com/newsletters.php for details.

Share

Filed Under: Big Pharma Watch Tagged With: FDA, MedWatch. Drug Label Change, predictive biomarkers for existing drugs

Primary Sidebar

Categories

  • Attention-Deficit/Hyperactivity Disorder Medications
  • Big Pharma Watch
  • Biotech Industry
  • Birth Control
  • Breast Cancer
  • cáncer de cuello uterino
  • Cancer Research
  • Cervarix
  • Cervical Cancer
  • Clinical Trials
  • Diabetes
  • Domestic Violence
  • Drug Approvals
  • Emotional Health
  • FDA
  • FDA Black Box Warning
  • FDA Clinical Trials
  • FDA Failure To Protect
  • FDA Product Recall
  • Follow The Money
  • Gardasil
  • Gardasil®
  • Gender Bias
  • Gender Politics
  • genital warts
  • Guillain-Barre Syndrome
  • Hormone Cycle
  • HPV Infection
  • HPV Vaccine
  • HRT
  • HRT Side Effects
  • Influenza A Virus H1N1 Strain
  • Mammograms
  • Mandatory HPV Vaccination Policies
  • Medical Technology
  • Menopause
  • MERCK Watch
  • MMR vaccine
  • National Vaccine Injury Compensation Program
  • PAP Test
  • Prescription Drug Side Effects
  • Proactive Nutrition
  • Product Recall
  • Reproductive Health
  • Sexual Dysfunction
  • Sleep Loss
  • STD Infection
  • Stroke
  • Take Action!
  • Uncategorized
  • Unwanted Pregnancy
  • Vaccination Policy
  • VAERS
  • vaginal yeast infection
  • Virginity
  • Weight Gain
  • Women's Health
  • Women's Rights
  • Work Place Issues
  • World Health Organization
  • Yeast Infection
  • Your Body/Your Self

Archives

  • February 2010
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • March 2006
  • September 2005
  • June 2005
  • May 2005
  • December 2004
April 2025
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Feb    

Breast Cancer

  • Cancer Advocacy

Health Advocacy

  • Women’s Universal Health Initiative

Syndication

  • FDA MedWatch

Tags

Big Pharma Watch Birth Control Breast Cancer Cancer Cancer Research CDC Cervarix Cervical Cancer Children's Health Exploitive Behavior FDA FDA Approvals FDA Clinical Trials FDA Failure To Protect FDA Press Release Follow The Money Gardasil Gardasil Adverse Event Gardasil® GlaxoSmithKline GlaxoSmithKline Cervarix Gynecology H1N1 "swine flu" virus H1N1 pandemic influenza preparedness efforts Health Advisory HPV HPV-Associated Cervical Cancer HPV-Vaccination HPV Infection HPV Vaccine HRT Human Papillomavirus (HPV) Infection Merck PAP SMEAR PAP Test Proactive Nutrition Questionable Medicine STD Infection STD Vaccination swine flu vaccine Swine flu vaccine production Take Action! Uncategorized Woman’s Health Your Body/Your Self

Copyright © 2010-2025 Hands On WordPress · All Rights Reserved